FDA Inspection 1274944 — Astellas Pharma Inc.

Astellas Pharma Inc. — FEI 3002807001

The FDA completed an inspection of Astellas Pharma Inc. on June 6, 2025 in Takaoka. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 6, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Takaoka (Japan)

Citations

IDCFRDescription
136121 CFR 211.100(a)Absence of Written Procedures
145221 CFR 211.113(b)Validation lacking for sterile drug products